Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

Fertility and Sterility

Volumn 75, Issue 1, 2001, Pages 38-45

  Fluker, Margo ^a   Grifo, James ^b   Leader, Arthur ^d   Levy, Michael ^e   Meldrum, David ^f   Muasher, Suheil J ^g   Rinehart, John ^h   Rosenwaks, Zev ⁱ   Scott Jr , Richard T ^j   Schoolcraft, William ^k   Shapiro, Daniel B ^c   Gordon, Keith ^a,l  

^a Genesis Fertility Centre   (Canada)

^b NEW YORK UNIVERSITY   (United States)

^c Fertility Center   (Canada)

^d Shady Grove Fertility Center   (United States)

^e Reproductive Partners Medical Group   (United States)

^f The Jones Institute for Reproductive Medicine   (United States)

^g Chicago Center for Human Reproduction   (United States)

^h WEILL CORNELL MEDICAL CENTER   (United States)

ⁱ REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY   (United States)

^j National Foundation for Fertility Research   (United States)

^k REPRODUCTIVE BIOLOGY ASSOCIATES   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Antagon; Controlled ovarian hyperstimulation; Embryo quality; Fertilization; Ganirelix acetate; Implantation rate; In vitro fertilization; Infertility; Leuprolide acetate; Oocyte; Open label; Pregnancy rate

Indexed keywords

CHORIONIC GONADOTROPIN; GANIRELIX; GONADORELIN ANTAGONIST; LEUPRORELIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; IMPLANTATION; INFERTILITY; INJECTION SITE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; OOCYTE DONATION; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULTRASOUND;

ADULT; CHORIONIC GONADOTROPIN; DOUBLE-BLIND METHOD; EMBRYO; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LEUPROLIDE; OVARY; PREGNANCY; PROGESTERONE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STIMULATION, CHEMICAL;

EID: 0035161913     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01638-1     Document Type: Article

References (12)

1. Induction of multiple follicular development for IVF
2. Future trends in infertility treatment; challenges ahead
3. Minimal ovarian stimulation for IVF; appraisal of potential benefits and drawbacks
4. Will GnRH antagonists be worth the wait?
5. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists; rationale and perspective
6. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part 1. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
7. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
8. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism
9. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
10. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer; a meta-analysis of randomized controlled trials
11. Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues